Pop Dan Dumitru, Hopîrtean Claudiu, Coşer Flavius, Dan Florina, Zah Teodor, Fekete Zsolt, Chiş Aurel, Tufăscu Gabriela, Udrea Adrian, Mihai Alina
Department of Radiation Oncology, Medisprof Cancer Center, Cluj-Napoca, Romania.
IOCN Oncology Institute "Prof. Dr. Ion Chiricuta" Cluj-Napoca, Romania.
Med Pharm Rep. 2022 Oct;95(4):410-417. doi: 10.15386/mpr-2362. Epub 2022 Oct 27.
The treatment of oligometastatic disease has become common practice as advanced radiotherapy techniques became more available. Lung is one of the main metastatic sites for a majority of cancers and many of these patients present with a limited metastatic disease burden. For these patients, SBRT (Stereotactic Body Radiation Therapy) represents a non-invasive treatment alternative. In this report we present our experience with our first series of patients with limited metastatic disease treated with lung SBRT. The purpose of this paper is to provide a qualitative and quantitative assessment of the lung SBRT treatment process and algorithm leading up to treatment delivery in a community-based radiotherapy department.
We have retrospectively reviewed our first series of 41 patients with lung oligometastases from various malignancies, treated using SBRT between March 2019 and December 2020. Demographic, technical and outcome data were analyzed.
A number of 45 lung metastases (in 41 patients) were treated with SBRT during the specified time period. The median age was 65.7 years old (range 33-83). 16 patients (39%) were treated for multiple lesions and the mean number of treated lesions was 1 (range1-3). Median dose prescribed was 50 Gy /5 fractions (median BED =77 Gy). The median intra-fraction displacements were: Vertical (0.23cm), Longitudinal (-0.27 cm), Lateral (-0.1 cm), Pitch [0.22°], Roll [0.15°], Rotation [0.32°]. The median session time was 40 minutes. All patients completed the prescribed course of treatment.Preliminary clinical data were recorded. With a median follow-up of 9 months, local control was recorded in all but one patient. At the last known follow-up, local control was recorded for 39 (85%) out of 45 treated lesions.
For lung SBRT, the required corrections at the time of treatment delivery are small, as long as strict protocols are implemented. Preliminary data for lung metastasis in oligometastatic patients support SBRT as a viable method of achieving high rates of early local control. These results need to be further confirmed in a larger cohort of patients with longer follow-up.
随着先进放疗技术的日益普及,寡转移疾病的治疗已成为常见的临床实践。肺是大多数癌症的主要转移部位之一,许多此类患者的转移疾病负担有限。对于这些患者,立体定向体部放疗(SBRT)是一种非侵入性的治疗选择。在本报告中,我们介绍了我们首批接受肺部SBRT治疗的寡转移疾病患者的经验。本文的目的是对社区放疗科在治疗实施前的肺部SBRT治疗过程和算法进行定性和定量评估。
我们回顾性分析了2019年3月至2020年12月期间使用SBRT治疗的首批41例来自各种恶性肿瘤的肺部寡转移患者。分析了人口统计学、技术和结果数据。
在指定时间段内,共对41例患者的45个肺转移灶进行了SBRT治疗。中位年龄为65.7岁(范围33 - 83岁)。16例患者(39%)接受了多个病灶的治疗,治疗病灶的平均数量为1个(范围1 - 3个)。处方中位剂量为50 Gy / 5次分割(中位生物等效剂量 = 77 Gy)。分次内位移的中位数为:垂直方向(0.23 cm)、纵向(-0.27 cm)、横向(-0.1 cm)、俯仰[0.22°]、横滚[0.15°]、旋转[0.32°]。中位治疗时间为40分钟。所有患者均完成了规定的疗程,并记录了初步临床数据。中位随访9个月时,除1例患者外,其余患者均实现了局部控制。在最后一次已知随访时,45个治疗病灶中有39个(85%)实现了局部控制。
对于肺部SBRT,只要严格执行方案,治疗实施时所需的校正量很小。寡转移患者肺转移的初步数据支持SBRT作为实现高早期局部控制率的可行方法。这些结果需要在更大规模的患者队列中进行更长时间的随访进一步证实。